tiprankstipranks
Trending News
More News >

Celcuity resumed with a Buy at Stifel

Stifel resumed coverage of Celcuity (CELC) with a Buy rating and $30 price target Stifel views gedatolisib as a uniquely differentiated asset poised to emerge as a standard-of-care treatment option within an increasingly competitive 2L+ HR+/HER2- metastatic breast cancer development landscape and thinks preclinical data clearly establishes gedatolisib’s enhanced potency vs. single-node PI3K/AKT/mTOR signaling pathway inhibitors, the analyst tells investors in a research note. The firm believes Q3 topline VIKTORIA-1 mPFS data in PIK3CA-wild-type patients represents favorable risk/reward at current valuation

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1